The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.
For more information about GOA, visit www.globaloncologyacademy.org.
Multiple Myeloma Care: Translating Evolving Practices to Oncology Nurses in Community Settings
Multiple Myeloma Care: Translating Evolving Practices to Oncology Nurses in Community Settings
Myeloma Matters: Prevention and Management of Bispecific Antibody–Associated Adverse Events in Multiple Myeloma
Myeloma Matters: Prevention and Management of Bispecific Antibody–Associated Adverse Events in Multiple Myeloma
Multiple Myeloma Care: Translating Evolving Practices to Oncology Nurses in Community Settings
Multiple Myeloma Care: Translating Evolving Practices to Oncology Nurses in Community Settings
Managing Infections, Cytopenias, and Other AEs Related to Bispecific Antibodies
Managing Infections, Cytopenias, and Other AEs Related to Bispecific Antibodies
Clinical Challenges With Triple-Class or Penta-Refractory MM
Clinical Challenges With Triple-Class or Penta-Refractory MM
Step-Up Dosing of Bispecific Antibodies: The Need for Hospitalization
Step-Up Dosing of Bispecific Antibodies: The Need for Hospitalization
Efficacy Data for Bispecific Antibodies in RRMM
Efficacy Data for Bispecific Antibodies in RRMM
The Evolving Treatment Paradigm for RRMM: The Role of Bispecific Antibodies
The Evolving Treatment Paradigm for RRMM: The Role of Bispecific Antibodies
Integrating Bispecific Antibodies Into Clinical Practice
Integrating Bispecific Antibodies Into Clinical Practice
Preventing CRS and Neurotoxicities Related to Bispecific Antibodies
Preventing CRS and Neurotoxicities Related to Bispecific Antibodies
Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials
Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials
Bispecific Antibodies: The Newest Immunotherapy on the Block for RRMM
Bispecific Antibodies: The Newest Immunotherapy on the Block for RRMM
Considerations for Dosing Bispecific Antibodies
Considerations for Dosing Bispecific Antibodies
Navigating NUT Carcinoma: Diagnosis and Treatment Strategies
Navigating NUT Carcinoma: Diagnosis and Treatment Strategies